Peptides / Brain and mood

Small molecule · 306.2 Da

Bromantane

Approved in RussiaBanned in sport

Bromantane is an adamantane-based drug approved in Russia as Ladasten for tiredness and weakness, and it is banned in sport. Most studies are in animals, on brain chemistry, physical activity and the immune system, with a few small studies in people. PepBank shows 36 results on bromantane from 8 studies in people, and 248 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Adamantilbromphenylamine, Bromantan, N-(4-bromophenyl)adamantan-2-amine, Ladasten, Ладастен

2D structure of Bromantane

Small molecule, shown without its saltPubChem 4660557

Evidence level: Mostly animal studies248 of 284 results come from studies in animals and lab cells. 8 studies in people.

Results in people

36

13% of 284 results

Results in animals

223

79% of 284 results

Results in lab cells

25

9% of 284 results

From computer models

0

0% of 284 results

Overview

Bromantane at a glance

What it is	Small molecule
Approval	Approved in Russia only (registered as Ladasten / Ладастен)
In sport	Banned in sport (WADA S6.A)
Studies	51 studies with results. 47 of them gave bromantane, with 284 results. 36 in people223 in animals25 in lab cells
Best study in people	Randomized controlled trial (2009)
Clinical trials	None registered
Community use	Stimulation and reduced anxiety

The science

What is bromantane?

An adamantane derivative used in Russia as Ladasten for asthenic conditions. WADA prohibits bromantan in competition.

284

Study results in PepBank

Bromantane structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Bromantane is a small molecule, not a peptide chain.

Formula

C₁₆H₂₀BrN

Molecular weight

306.2 g/mol

CAS number

87913-26-6

Development

Zakusov Institute of Pharmacology. Highest phase: past the trial stage (see status).

Identifiers

PubChem 4660557, ChEMBL CHEMBL4303520, UNII N1ILS53XWK

SMILES and InChIKey

InChIKey
LWJALJDRFBXHKX-UHFFFAOYSA-N

SMILES
C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br

See charge, composition and 3D structure on the Scientific page

The evidence

What bromantane studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies248 of 284 results come from studies in animals and lab cells. 8 studies in people.

Daily life and fitness

32 results · 9 in people · 23 animal

In healthy volunteers, bromantan improved functional state compared with placebo. Voenno-meditsinskii zhurnal, 2000

Top results

In healthy volunteers, bromantan improved functional state compared with placebo. (Voenno-meditsinskii zhurnal, 2000)
In patients with neurasthenia, ladasten was better than placebo in how fast and how much main asthenic symptoms fell. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009)
In patients with neurasthenia, self-rated ladasten effects were not linked to personal features. (Eksperimental'naia i klinicheskaia farmakologiia, 2011)

Mood, stress and behavior

19 results · 6 in people · 13 animal

In patients with psychoautonomic syndrome, the study reported that ladasten improved anxiety-depressive disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010

Top results

In patients with psychoautonomic syndrome, the study reported that ladasten improved anxiety-depressive disorders. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In untired men, bromantan did not change subjective state compared with placebo. (Voenno-meditsinskii zhurnal, 2000)
In patients with psychogenic asthenic disorder, ladasten showed stimulant effects. (Eksperimental'naia i klinicheskaia farmakologiia, 2006)

Overall treatment results

3 results · 3 in people

In patients with psychoautonomic syndrome and asthenia, 76.0% responded on CGI-S during ladasten treatment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010

Top results

In patients with psychoautonomic syndrome and asthenia, 76.0% responded on CGI-S during ladasten treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In healthy volunteers, ladasten effects were stronger in individuals prone to stress responses. (Eksperimental'naia i klinicheskaia farmakologiia, 2009)
In patients with psychoautonomic syndrome and asthenia, 90.8% responded on CGI-I during ladasten treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)

Brain and nerves

30 results · 1 in people · 29 animal

In patients with psychoautonomic syndrome, the study reported that ladasten improved autonomic dystonia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010

Top results

In patients with psychoautonomic syndrome, the study reported that ladasten improved autonomic dystonia. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In rats, pup exploratory behavior after maternal bromantan was insignificantly lower than controls. (Neurotoxicology and teratology, 2001)
In cats under anesthesia, bromantan reduced induced ganglion electrical potential compared with the initial level at specified stimulation frequencies. (Eksperimental'naia i klinicheskaia farmakologiia, 2000)

Memory and thinking

2 results · 1 in people · 1 animal

In healthy volunteers with mental fatigue, ladasten improved psychophysiological measures. Eksperimental'naia i klinicheskaia farmakologiia, 2009

Top results

In healthy volunteers with mental fatigue, ladasten improved psychophysiological measures. (Eksperimental'naia i klinicheskaia farmakologiia, 2009)
In rats, bromantan improved memory processes. (Eksperimental'naia i klinicheskaia farmakologiia, 1999)

Sleep

1 result · 1 in people

In patients with psychoautonomic syndrome, the study reported that ladasten improved sleep disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010

Top results

In patients with psychoautonomic syndrome, the study reported that ladasten improved sleep disorders. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)

All 51 bromantane studies by area Open the Scientific page

Key bromantane studies

Studies in people come first, then studies in animals and in the lab.

People
[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]
Neznamov et al. 2009 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · cited by 0
2 results
People
[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]
Voznesenskaia et al. 2010 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 728 people · cited by 1
10 results
People
[The neuro- and psychophysiological effects of bromantane]
Viatleva et al. 2000 · Voenno-meditsinskii zhurnal · 10 people · cited by 1
8 results
People
[Characteristics of ladasten effect in neurasthenia patients with various EEG parameters]
Neznamov et al. 2008 · Eksperimental'naia i klinicheskaia farmakologiia · cited by 2
6 results
People
[Experimental rationale for the use of drugs to increase the resistance of the human body to the combined action of carbon monoxide and hyperthermia]
Sedov et al. 1993 · Meditsina truda i promyshlennaia ekologiia · cited by 1
1 result

All 51 Bromantane studies

Bromantane clinical trials

ClinicalTrials.gov lists no trial of bromantane. A trial under another name may exist.

Status and safety

Is bromantane approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S6.A.

Yes. Approved in Russia only (registered as Ladasten / Ладастен). No FDA approval and no central EU authorisation (EMA). Banned in sport (WADA S6.A).

Laws and labels change, so check the regulator for the current status.

Bromantane side effects and safety

PepBank has 97 safety results from studies of bromantane. 6 of them come from studies in people.

Safety results from studies (97)

In patients with neurasthenia, the study found no withdrawal syndrome after ladasten treatment ended. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009)
In patients with psychoautonomic syndrome, 3% had adverse effects during ladasten treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In patients with neurasthenia, self-rated tolerability of ladasten was comparable with placebo. (Eksperimental'naia i klinicheskaia farmakologiia, 2011)
In healthy volunteers, a single ladasten dose showed no behavioral toxicity. (Eksperimental'naia i klinicheskaia farmakologiia, 2009)
In patients with psychoautonomic syndrome, 0.8% discontinued ladasten treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In patients with psychoautonomic syndrome, the study found no serious adverse effects during ladasten treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In rats, maternal general state did not differ significantly from controls during or after bromantan treatment. (Neurotoxicology and teratology, 2001)
In male rats, bromantan produced an unreliable decrease in sperm amount. (Eksperimental'naia i klinicheskaia farmakologiia, 2000)
In rats, lower bromantane doses stimulated behavioral activity. (Bulletin of experimental biology and medicine, 2002)
In rats, bromantan initially lowered body temperature, then slightly raised it in the second month. (Eksperimental'naia i klinicheskaia farmakologiia, 2000)
In rats, parental bromantan exposure did not significantly change the number of females giving birth compared with controls. (Eksperimental'naia i klinicheskaia farmakologiia, 1999)
In rats, chronic bromantan injection raised hemoglobin levels. (Eksperimental'naia i klinicheskaia farmakologiia, 1999)
In mice, the intraperitoneal bromantan dose lethal to half the animals was 8100 mg/kg. (Eksperimental'naia i klinicheskaia farmakologiia, 1999)
In rats, maternal activity did not differ significantly from controls during or after bromantan treatment. (Neurotoxicology and teratology, 2001)
In rats, bromantan had no adverse effect on maternal body weight. (Neurotoxicology and teratology, 2001)
In rats, bromantan had no adverse effect on gestation length. (Neurotoxicology and teratology, 2001)
In rats, the number of mothers delivering after bromantan did not differ from controls. (Neurotoxicology and teratology, 2001)
In rats, stillbirths occurred in all litters, but controls had fewer than bromantan groups. (Neurotoxicology and teratology, 2001)
In rats, one mother in the first bromantan group delivered a pup with a head hematoma. (Neurotoxicology and teratology, 2001)
In rats, low-dose maternal bromantan reduced litter size compared with controls. (Neurotoxicology and teratology, 2001)
In rats, intermediate-dose maternal bromantan increased litter size compared with controls. (Neurotoxicology and teratology, 2001)
In rats, high-dose maternal bromantan reduced litter size compared with controls. (Neurotoxicology and teratology, 2001)
In rats, newborn sex ratios did not differ significantly between bromantan groups and controls. (Neurotoxicology and teratology, 2001)
In rats, pups after intermediate-dose maternal bromantan had greater mortality over the first 3 months than controls. (Neurotoxicology and teratology, 2001)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
50 to 100 mg daily	Human	human	Not reported	28 days	Trial in people without random groups · n = 728	Voznesenskaia 2010
0.25 g	Human	human	Not reported	Not reported	Trial in people without random groups	Sedov 1993
15 mg	Human	human	Not reported	single dose	Trial in people without random groups	Reutova 2011
100 mg	Human	human	Not reported	single dose	Trial in people without random groups	Bogdan 2009
30, 150 and 600 mg/kg daily	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
30 mg/kg	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
150 mg/kg	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
600 mg/kg	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
150 and 600 mg/kg	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
30 and 600 mg/kg	Animal	rat	oral	16 days	Study in live animals	Iezhitsa 2001
30 mg/kg	Animal	mouse	intraperitoneal	once or for 5 days	Study in live animals	Tallerova 2011
30 and 50 mg/kg	Animal	mouse	Not reported	5 injections	Study in live animals	Tallerova 2011
30 mg/kg daily	Animal	rat	Not reported	2 months	Study in live animals	Khamidova 2000
30 and 200 mg/kg daily	Animal	rat	Not reported	2 weeks	Study in live animals	Khamidova 2000
30 mg/kg	Animal	mouse	intraperitoneal	5 days	Study in live animals	Tallerova 2014
50 mg/kg	Animal	rat	oral	Not reported	Study in live animals	Kudrin 1995
50 mg/kg	Animal	rat	Not reported	1-12 h	Study in live animals	Vakhitova 2004
50 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Vakhitova 2004
30-300 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
600-9,600 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
600 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
>600 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
300-600 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
>10 g/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
>5 g/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
30 and 600 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Iezhitsa 2002
40-50 mg/kg	Animal	mouse	oral	Not reported	Study in live animals	Seredenin 1999
5 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Morozov 1999
1-20 mg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Morozov 1999
lower than 5 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Morozov 1999
1-50 mg/kg	Animal	cat	intravenously	Not reported	Study in live animals	Morozov 1999
30-600 mg/kg	Animal	Not reported	Not reported	Not reported	Study in live animals	Morozov 1999
50 mg/kg	Animal	rat	intragastric	Not reported	Study in live animals	Salimgareeva 2011
50 mg/kg	Animal	rat	Not reported	single treatment	Study in live animals	Yamidanov 2010
50 mg/kg	Animal	rat	intraperitoneal	single dose	Study in live animals	Zimin 2010
50 mg/kg	Animal	rat	Not reported	single administration	Study in live animals	Salimgareeva 2009
10 and 20 mg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Levina 2006
30 mg/kg	Animal	rat	intraperitoneal	Not reported	Study in live animals	Iarkova 2005
10 mg/kg	Animal	mouse	Not reported	Not reported	Study in live animals	Levina 2005
50 mg/kg	Animal	rat	Not reported	Not reported	Study in live animals	Vakhitova 2004

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

PsychonautWiki reports oral bromantane use for stimulation and reduced anxiety. A Russian label reprint provides a separate medicinal regimen.

Reported routines and cautions

What people use it for

Stimulation and reduced anxietyS1

Reported regimens

Regimens that community sources report for Bromantane. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
PsychonautWiki common amount	oral	50 to 100 mg per dose	Not stated	Not stated	Single community wiki. Frequency and course length are not specified for this amount.	S1
Ladasten label reprint for asthenic conditionsOfficial label dosing of an approved product	oral	50 to 100 mg per dose	twice daily	2 to 4 weeks	Single manufacturer-approved instruction reprint dated 10 July 2012. RLS carries pharmaceutical advertisements. This is historical label use. The current official label revision remains unconfirmed.	S2

Reported side effects

Dehydration (PsychonautWiki marks this claim citation needed)S1
Increased blood pressure (PsychonautWiki marks this claim citation needed)S1

Reported benefits (claims, not shown in trials)

StimulationS1

Community sources

S1Bromantane, PsychonautWiki (opens in a new tab)psychonautwiki.org
S2Ladasten manufacturer-approved 2012 instruction reprint, RLSwww.rlsnet.rucarries seller links, not linked
S3Russian national register search for Ladasten (opens in a new tab)grls.rosminzdrav.ru

Gaps

The official current GRLS detail entry and label revision remain unconfirmed. Vidal and a register mirror report replacement registration ЛП-№(005486)-(РГ-RU), dated 16 May 2024. R1 specifies neither frequency nor course duration. R2 remains a separate 2012 label reprint.

Questions and more

Ask a question about bromantane

The answer links to every study it uses.

What does the evidence say about bromantane?Is bromantane tested in people?Compare with Cerebrolysin Compare with Delta sleep-inducing peptide (DSIP)

Sources

Database: PepBank data for bromantane (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about bromantane

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).